

Board of Directors (in Public)

Item: 6.1.5a
Subject: Integrated Performance Committee BAF Key Issues Report
Date of Meeting: 26th November 2024
Prepared by: James Thomson, Chief Finance Officer,
 Jonathan Mathews, Chief Operating Officer
Presented by: Claudette Elliot, Chair Integrated Performance Committee
Meeting Held: 21st October 2024

Agenda Item	Lead Exec	Assurance Received	New/ Emerging Risks	Actions/ Comments
Trust SOF	JM	IPC SOF report presented and discussed.	Areas of risk have been identified and mitigations and recovery plans in place where possible.	Activity continues to be monitored and updates provided through Operational Board & Integrated Performance Committee.
Productivity Proposal	JM/BD	Update provided on the Productivity Proposal. Trust looking to align the Productivity Improvement Plan with the Trust SOF. Areas for improvement have been identified and governance structures are now in place.	-	Update to be provided to IPC and Board of Directors in the new year.
Cardiac MRI	JM	Update provided on Cardiac MRI	Increase in Cardiac MRI referrals	Ongoing actions monitored through weekly performance meeting and daily PTL oversight.
Long Waiters	JM	Update provided on long waiter position.	Surgeon sickness and unavailability. Patients requiring additional diagnostic testing causing delays in pathways. Increase in urgent demand. Financial cost pressure	Ongoing actions monitored through weekly performance meeting

Diagnostics within Cancer	JM	Update provided on diagnostics within cancer	EBUS capacity. Increased referrals.	Close monitoring of delays in pathways via PTLs and escalation. Cancer Action Plan in place and monitored via Trust Cancer Board.
Finance Report (including CIP & Capital)	JT	<p>Assurance provided on the Trust financial position at month 6, 2024/2025.</p> <p>The Trust has achieved a £5,698k surplus in the year to date, an adverse variance of £943k.</p>	<p>The Trust's planned surplus for the year is £14.1m in response to the stretch target given by the ICB. The Trust continues to forecast achievement of the plan.</p> <p>Key risks include the CIP plan, delays to the expansion of the Targeted Lung Health Check programme and overspends in a number of areas, predominantly theatres, Cath labs and drugs.</p> <p>Emergency pressures are driving higher spend levels, but the block contract for non-elective care means that there is no growth in income to support it. Although pay costs have remained largely stable and within budget, there are pockets of overspends that need to be addressed.</p>	CIP delivery and managing the budgetary overspends in pay and non-pay remain key areas of focus.
M6 – M12 Forecasting	JT	<p>Update provided on the month 6 to month 12 forecast position.</p> <p>Details forecast based on divisional and corporate assumptions.</p>	<p>Elective Recovery Fund targets.</p> <p>Variable Contracts</p> <p>Pay Award</p> <p>CIP</p>	Monitor future monthly financial performance against the plan and evaluate the best/worst case scenarios.

--	--	--	--	--